Nigel Killeen

Title: The Innovative Contributions of Nigel Killeen

Introduction

Nigel Killeen is a notable inventor based in South San Francisco, California. He has made significant contributions to the field of biotechnology, particularly in the development of modified NKG2D ligands. His work focuses on enhancing the capabilities of engineered immune cells to target and eliminate virus-infected cells.

Latest Patents

Killeen holds a patent for "Modified non-natural NKG2D ligands that selectively deliver attached heterologous molecules to non-natural NKG2D receptors on CAR-cells." This patent relates to the production of modified, non-natural α1-α2 domains of NKG2D ligands. These ligands are designed to attach polypeptides with specific target-binding properties, such as antibodies, which can be selectively delivered to Chimeric Antigen Receptors (CARs) on engineered mammalian cells. This innovative approach allows for the targeting of surface-expressed molecules on virus-infected cells, enabling engineered immune cells to effectively attack and ablate these cells.

Career Highlights

Throughout his career, Killeen has worked with prominent organizations in the biotechnology sector. He has been associated with Xyphos Biosciences Inc. and the J. David Gladstone Institutes. His work in these institutions has contributed to advancements in immunotherapy and cellular engineering.

Collaborations

Killeen has collaborated with notable professionals in his field, including Kaman C Kim and Eytan Herzig. These collaborations have furthered research and development in the area of engineered immune responses.

Conclusion

Nigel Killeen's innovative work in the field of biotechnology, particularly with modified NKG2D ligands, showcases his commitment to advancing medical science. His contributions have the potential to significantly impact the treatment of viral infections through engineered immune cell therapies.